Related Experiment Video
Updated: Jul 8, 2025
04:48
Establishing a Severe Corneal Inflammation Model in Rats Based on Corneal Epithelium Curettage Combined with Corneal Sutures
Published on: November 22, 2024
307
Corneal epithelial changes in a patient treated with belantamab mafodotin
Leandro Inferrera1, Rosa Giglio1, Daniele Tognetto1
1Department of Medical, Surgical Sciences and Health, Eye Clinic, University of Trieste, Trieste, Italy.
Taiwan Journal of Ophthalmology
|December 13, 2023
Summary
Belantamab mafodotin, a treatment for multiple myeloma, can cause temporary corneal changes and vision reduction. These effects improved after discontinuing the drug, highlighting the need for careful monitoring.
Area of Science:
- Ophthalmology
- Oncology
- Pharmacology
Background:
- Multiple myeloma (MM) is a hematologic malignancy.
- Belantamab mafodotin (BM) is an antibody-drug conjugate targeting B-cell maturation antigen used for refractory MM.
Observation:
- A 55-year-old male with refractory MM developed bilateral reduced visual acuity and dry eye symptoms 33 days after starting BM.
- Slit-lamp examination revealed diffuse microcystic corneal epithelial changes.
Findings:
- BM treatment discontinuation led to gradual improvement in visual acuity and resolution of corneal changes over 90 days.
- Corneal epithelial alterations are a common side effect of belantamab mafodotin therapy.
Implications:
- Close collaboration between ophthalmologists and oncologists is essential for managing ocular side effects of BM.
- Monitoring visual acuity and corneal health is crucial for patients undergoing BM treatment.
Keywords:
Adverse effectsbelantamabepithelial changesmafodotinrelapsed or refractory multiple myeloma
